Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Boucher

Showing results (191-200 of 193) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 193 results.
Acta Physiologica (Oxford, England)|March 27, 2014
Modular organization of cardiac energy metabolism: energy conversion, transfer and feedback regulationR Guzun, T Kaambre, R Bagur, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2024
H<sub>2</sub> inhalation therapy in patients with moderate COVID-19 (H<sub>2</sub>COVID): a prospective ascending-dose phase I clinical trialC Salomez-Ihl, J Giai, M Barbado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excisionCheryl A London, Phyllis B Malpas, Stacey L Wood-Follis, et al.
Pageof 20

Showing results (191-200 of 193) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 193 results.
Acta Physiologica (Oxford, England)|March 27, 2014
Modular organization of cardiac energy metabolism: energy conversion, transfer and feedback regulationR Guzun, T Kaambre, R Bagur, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2024
H<sub>2</sub> inhalation therapy in patients with moderate COVID-19 (H<sub>2</sub>COVID): a prospective ascending-dose phase I clinical trialC Salomez-Ihl, J Giai, M Barbado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excisionCheryl A London, Phyllis B Malpas, Stacey L Wood-Follis, et al.
Pageof 20